Chair

Professor Whelan is a highly experienced clinician and researcher, having spent nearly 30 years studying the treatment of sarcomas and managing cancer in teenagers and young adults. He is a Consultant Medical Oncologist and Lead at one of the largest sarcoma services in Europe in the University College London Hospital. He is a Professor of Cancer Medicine at UCL and is co-chair of the Sarcoma Advisory Group of the London and South East Sarcoma Network, which serves a population of approximately 15 million people.

Professor Whelan major programmes in young people’s cancer and sarcoma. He established and co-ordinated the EUROEWING Consortium (www.euroewing.eu) and has served on the boards of the Connective Tissue Oncology Society and the European Musculoskeletal Oncology Society. He chaired the National Cancer Research Institute Teenage and Young Adult Clinical Studies Group for nine years, and was a long standing member of the Sarcoma Clinical Studies Group, of which he continues to be an active member of its bone sarcoma sub group.

Professor Whelan is a member of the NHS England Cancer Surgery Clinical Reference Group, and leads on providing expert clinical guidance for specialised commissioning of sarcoma services.

Dr Beggs is the founder of the Beggs Lab and Reader in Cancer Genetics & Surgery in the Institute of Cancer and Genomic Sciences at the University of Birmingham, as well as the Consultant Colorectal & General Surgeon at the Queen Elizabeth Hospital, Birmingham.

He is part of the West Midlands multi-disciplinary team delivering the pelvic exenteration service and is a member of the National Cancer Research Institute (NCRI) Colorectal Cancer Clinical Support Group (CSG).

Dr Beggs has a special interest in the multi-omic profiling of cancers, in particular, colorectal, oesophageal and sarcoma and the Beggs Lab is part of the Human Model Cancers Initiative. 

He is a member of the Human Cancer Models Initiative, and a member of the consortium that sequenced the reference human genome.

Dr Behjati is a Group Leader at the Wellcome Sanger Institute and Consultant Paediatric Oncologist at Addenbrooke’s Hospital, Cambridge. His research is focused on unravelling the origins of cancer, using a variety of cutting edge nucleic acid sequencing technologies. Previously he has defined the somatic genetic basis of different subtypes of sarcoma, as part of the UK contribution to the International Cancer Genome Consortium. He continues to pursue his interest in sarcoma genomics through the Genomics England sarcoma programme and his own research. Dr Behjati read medicine at the University of Oxford and pursued clinical academic training in paediatric oncology in London and Cambridge.

With a background in Palliative care and medicine, and teamed with a special interest in breathlessness, Dr Booth began holding an NHS R&D training fellowship that then led to the foundation of the Breathlessness Intervention Service.

She is an Honorary Consultant and Associate Lecturer at the University of Cambridge, as well as an Honorary Research Fellow at the Cicely Saunders Institute of Palliative Care and Policy at King’s College, London.

Professor Brennan is a Consultant Paediatric Oncologist and Honorary Senior Lecturer at the Royal Manchester Children’s Hospital, with over 30 years as a qualified doctor, as well as further training in General Paediatrics, Paediatric and Adolescent Oncology and an MD in the late effects of Childhood Leukaemia.

She also has extensive experience in sarcoma as the Clinical Lead on the European paediatric Soft tissue sarcoma Study Group (EPSSG), the non-rhabdyomyosarcoma soft tissue sarcomas study for the UK (NRSTS) and Internataional/UK Euro Ewing 2012 Study and as a member of the Euro Ewing Consortium.

Bernadette is also a member of the Sarcoma Clinical Studies Group, the Children’s Cancer and Leukaemia Group (CCLG), the Rare Tumour Group, the EXPeRT European Rare Tumour Group and chairs the Young Onset Soft-Tissue Sarcoma (YOSS) subgroup.

Professor Burchill is the Professor of Cancer Research at the University of Leeds and Scientific director of the Children’s Cancer Research Group at St James’s University Hospital, which is a translational research programme she established in 1992.  Her primary research interests in the metastatic drug resistant disease have led her to become the chair of the Society International of Oncology Paediatric-Neuroblastoma (SIOPEN) who run clinical trials, the European Ewing’s Consortium (EEC) who monitor molecular biological studies, and is the co-chair of the International Neuroblastoma Response Criteria (INRC) Bone Marrow Working Group who lead international circulating biomarker studies for children with neuroblastoma.

Sue is also a member of the NCI CCL Neuroblastoma Clinical Studies Group, the NCI Sarcoma Clinical Studies Group and the NCRI Bone Sarcoma subgroup. She continues to inspire through supervising undergraduate and postgraduate students.

Dr Campbell Hewson has been a Consultant Paediatric Oncologist at the Great North Children’s Hospital in Newcastle upon Tyne since 2003. He specialises in Solid Tumours, Early Phase Trials and Palliative care.

As a strong advocate for new therapies he jointly established a Northern Network for Children’s Cancer Early Phase trials –the ”INCLuDE” network- which encompasses Northern England, Scotland and Northern Ireland. This network has been the template for the networks which now cover the whole UK.

He is active as a member of the UK Experimental Medicines Cancer Group Paediatric Network Strategy group and the European Innovative Therapies for Children’s Cancer consortium.

He is the Specialty Group lead for Children’s Research NIHR CRN North east and North Cumbria, leads children’s clinical research for Newcastle upon Tyne as well as Children’s Cancer Theme lead for the NIHR CYPMed Tech Cooperative.

He is Principal Investigator for a number of late and early phase studies for sarcomas and a member of the NCRI Sarcoma clinical Study group.

Dr Carter is a Clinical Senior Lecturer in Experimental Cancer Medicine at the University of Manchester.  She is also an Honorary Consultant in Medical Oncology at the Christie NHS Foundation trust.

She is the principal investigator on a portfolio of early phase clinical trials in the Experimental Cancer Medicine Team. In her research she focuses on the development of early phase clinical trials for new anti-cancer treatments and translational assays.  She also researches the role of supportive care treatments for clinical trial patients. 

She is a member of the National Cancer Research Institute Sarcoma Clinical Studies Group.

Prof Cool is a Consultant Orthopaedic and Oncological Surgeon at The Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, as well as an Honorary Senior Lecturer at the University of Manchester.

Paul has specialist interests in soft tissue and bone sarcoma, and tumour-like conditions.

With an undergraduate at Queen’s College, Cambridge and the Royal Free Hospital, London followed by an MD in oesophageal cancer at the University of Birmingham and Fellowships across Europe, Mr Desai was appointed as the Consultant Surgeon at the Midlands Abdominal and Retroperitoneal Sarcoma Unit in 2011.

Anant is on the editorial advisory board for the European Journal of Surgical Oncology, the Chair of the West Midlands Sarcoma Advisory Group and leader of the regional soft tissue sarcoma multi-disciplinary team. He has extensive experience of research and contributes to a number of Journals as a reviewer. He is an active member of the NCRI Sarcoma Research Group

With nearly 30 years in the medical field, Professor Flanagan specialises in the pathology of soft tissue and bone tumours has led to many successful research studies into gene sequencing to help clinicians make informed decisions to improve patient’s quality of life while experiencing sarcomas such as Chordoma, Chondrosarcoma and Osteosarcoma. She is a Consultant Histopathologist in the London and South East Sarcoma Network at the Royal National Orthopaedic Hospital & University College Hospital, as well as the Department Head of Pathology and Research Group leader in Genetics and Cell Biology of Sarcoma at UCL’s Cancer Institute.

Professor Flanagan is additionally the president of the Pathological Society of Great Britain and Ireland, the joint lead of the International Cancer Genome Consortium bone project, a Trustee at The Jean Shanks Foundation and the Skeletal Cancer Action Trust (SCAT), a member of The Chordoma Foundation (USA) and is on the editorial board of the Journal of Pathology. Adrienne has published over 170 peer-reviewed papers and was awarded an OBE in 2017 for services to cancer research.

Consultant Orthopaedic Surgeon and Cancer Lead, Royal National Orthopaedic Hospital, Stanmore

Consultant Orthopaedic Surgeon and Cancer Lead, Royal National Orthopaedic Hospital, Stanmore

Mr Gerrand began as a Consultant Orthopaedic Surgeon and Clinical lead for Cancer at the Royal National Orthopaedic Hospital in 2018, having previously worked for the Newcastle Upon Tyne Hospital NHS Foundation Trust for 17 years. With a research interest in surgical aspects of sarcoma care and innovation in the NHS, he specialises in the management of patients with bone and soft tissue tumours, including bone and soft tissue sarcomas.

Craig is a Board member of the British Sarcoma Group and sits on the NHS England Specialised Cancer Surgery Clinical Reference Group to delivery commissioning of NHS Services

After receiving his PhD from Massachusetts Institute of Technology (MIT) in Biological Engineering in 2008, Dr Huang started his laboratory at the Institute of Cancer Research (ICR)as an Institute Fellow in 2009 where he held a Sir Henry Wellcome Fellowship. This was followed by a promotion to a tenure-track in the Division of Cancer Biology. He is now the Team Leader in the Division of Molecular Pathology at the ICR holds a Cancer Research UK Career Establishment Award.

Paul is a member of the Sarcoma Clinical Studies Group at the National Cancer Research Institute and the Scientific Evaluation Committee of the European Research Area Network (ERA-NET) TRANSCAN-2 for joint translational cancer research. His research focuses on the use of systems biology and molecular pathology strategies to understand aberrant signalling networks and drug resistance in sarcomas and lung cancer, with the goal of developing biomarkers and new therapies for these diseases.

Professor Hupp is the Chair and Professor of Experimental Cancer Research at the University of Edinburgh and part of the interdisciplinary Doctoral Training Centre in cell & proteomic technologies team.

Ted has research into how insights into cancer progression pathways, particularly sarcomas, can identify therapeutic strategies.

Currently working as a Consultant Radiologist at the Royal Marsden Hospital, Dr Messiou is also a member of numerous multidisciplinary teams for soft tissue sarcoma, melanoma and myeloma. She is an Honary Faculty member at The Institute of Cancer Research, as well as a member of the Royal College of Radiologists Academic Committee, the NCRI Expert Advisory Panel and the Steering Committee of the EORTC Soft Tissue and Bone Sarcoma Group.

Christina is particularly focused on the benefit of whole body MRI for patients, including the use of machine learning to translate sophisticated tumour analysis into clinical practice, as well as defining tumour heterogeneity to guide future therapy,

Sophie Postel-Vinay is currently Physician Scientist at the Drug Development Department and U981 INSERM research unit of Gustave Roussy Cancer Campus, where she leads an independent research group.

She received her medical degree from the Université René Descartes Paris V in 2010, and joined the faculty in November 2013 after completion of her PhD. She completed her residency training in Paris, and spent 18 months at the Royal Marsden Hospital in London in the Drug Development Unit.

Dr Postel-Vinay is member of AACR and ASCO, from which she received a merit award in 2010. She is also an ESMO member and received the ESMO translational research fellowship for her PhD that was performed at the Institute of Cancer Research (London), focusing on DNA repair and synthetic lethality.

Her research activity focuses on chromatin remodeling and its interplay with DNA damage repair and immune modulation in solid tumor cancer models. Her research interests include DNA repair, chromatin remodeling and synthetic lethality, sarcoma, drug development, predictive biomarkers and emerging targets.

Dr Sisley is a Senior Lecturer at the Department of Oncology at the University of Sheffield with a specialisation in sarcomas and an interest in rare tumours.

Karen's research focuses on the genetic changes related to subtypes of rare tumours, and the impact that these have on tumour behaviour.

Professor Spicer is a Consultant in Medical Oncology at Guy’s & St. Thomas’ Hospitals and the Professor of Experimental Cancer Medicine at King’s College London. He runs the King’s Health Partners Cancer Early Phase Trials programme and co-leads the King’s Experimental Cancer Medicine Centre, funded by Cancer Research UK/National Institute for Health Research.

As well as this, James set up and runs the Cancer Early Phase Trials programme at Guy’s & St. Thomas’ Hospitals and is the Clinical Lead in the Clinical Research Facility at Guy’s Hospital. His special interests are of patients with thoracic malignancies and understanding new treatment options.

A Medical Oncologist at the London Sarcoma Service (as part of the Royal National Orthopaedic Hospital & University College London Hospital), Dr Strauss specialises in the systemic treatment of soft tissue and bone sarcomas in teenagers and adults. Her research focuses on identifying new targets for therapy in osteosarcoma and Ewing's sarcoma, as well as developing early phase clinical trials.

Sandra is also the principal investigator for a number of clinical trials and is a member of the National Cancer Research Institute Clinical Studies Group for sarcoma and bone subgroup, as well as the EORTC Soft Tissue and Bone Sarcoma Group.

A Clinical Professor at The University of Leeds and Lead Consultant in Medical Oncology, Prof. Velikova’s clinical work focuses on the systemic treatment of breast cancer patients with early and advanced disease, including chemotherapy, endocrine therapy and targeted treatments.

Her research also focuses on Quality of Life in people with breast cancer and leads the QoL sub-studies of large national and international research trials. This led to her working on the development of a crucial web-based system for collecting self-reported data into the adverse effects during and after chemotherapy and radiotherapy treatments, and integrating this with electronic patient records that generate alerts for clinicians and support immediate patient care.

Galina currently chairs the National Cancer Research Institute (NCRI) Psychology Oncology and Survivorship Clinical Studies Group and is an elected Board member of the European Organisation for Research and Treatment of Cancer (EORTC). She has previously chaired the British Psychosocial Oncology Society (BPOS) and the EORTC Quality of Life Group. 

With training at UCL and Royal Medical School, and a postgraduate in general medicine, Dr Wood now specialises as a Consultant in Palliative Medicine at The Royal Marsden and Royal Brompton Hospitals.

Jayne is also the Clinical Lead for education and the Training Programme Director for core medical trainees across The Royal Marsden.